# A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

> **NCT07343960** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 20 (estimated)

## Conditions studied

- Moderate Hepatic Impairment

## Interventions

- **DRUG:** Capivasertib

## Key facts

- **NCT ID:** NCT07343960
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07343960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07343960, "A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07343960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*